AttOaSA rejection is a complex process, which requires interactions between different cell types and a variety of soluble factors, such as cytokines. In this review we discuss the role of cytokines in the induction and effector phases of the rejection process and in the induction and maintenance of allospecific graft tolerance. Furthermore, we discuss the feasibility of clinical graft function monitoring by measuring cytokines and the possibilities for intervention in the cytokine network in order to inhibit graft rejection and eventually obtain graft acceptance.
One of the immune responses in which cytokines are considered to play an important role is allograft rejection. The process of rejection has been studied carefully and starts to become more clear. [1] [2] [3] During the induction phase of rejection, T-cell receptor (TcR) recognition of the foreign MHC molecule results in Tcell activation, expression of the interleukin (IL)-2 receptor (R) and production IL-2, which in an autocrine fashion induces clonal expansion of the activated T cells. During T cell activation, soluble (s)IL-2R are released. It is thought that CD4 T lymphocytes are essential for initiation of graft rejection and CD8/T cells are more important in the effector phase of rejection. In this phase, production of IL-2 and other cytokines induces influx and proliferation of CD8 cytotoxic T cells, natural killer (NK) cells and macrophages. This inflammatory process will lead to tissue destruction and dysfunction of the graft. Cytokines can influence this process at several levels (Table 1) . IL-1, produced by macrophages, acts as an accessory signal from the antigen presenting cell (APC) for T cell proliferation. 6, 7 IL-2 is a growth factor for T lymphocytes, induces T lymphocyte cytotoxicity and stimulates NK cell activity. Interferon (IFN)-7 activates macrophages, cytotoxic T cells and NK cells and induces increased expression of MHC class and II molecules in this way increasing the allogenicity of the graft. Tumour necrosis factor (TNF)-{x increases the MHC class expression and activates neutrophils. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Apart from these activities, cytokines may have direct cytotoxic effects on the grafted tissue. 13 Since CD4 T cells are of such importance for graft rejection, T-helper (Th)l-Th2 subsets have been studied for their potential role in regulating the rejection process. Both in mice and in human, different Th cell clones have been described, which can be distinguished by the different sets of cytokines they produce. 14, 15 Thl cells produce IL-2, IFN-, and 54 and renal allografts with stable graft function. 55 In a rat kidney allograft model, in which tolerance was induced by DST, graft infiltrating cells from tolerant rats were unable to produce IL-2 in vitro, expressed lower levels of the IL-2R and showed lower proliferation in response to IL-2 than cells from untreated rats. 56 In a comparable model, tolerized rat heart allografts showed a lower expression of IL-2 and IFN-7 mRNA and a different kinetics of these messages than rejecting allografts. 57 After induction of tolerance, using several different strategies, it has been shown that IL-2 and IFN-y mRNA were downregulated, whereas IL-4 and IL-10 (Th2 cytokines) mRNA expression remained at the same level or even increased. 58 6 Furthermore, local effects of the mAb, such as diminished mononuclear cell infiltration, no expression of MHC class antigens and modification of immunohistologic staining pattern of TNF-0t, were readily visible. 7, 9, 72 Another explanation for the disappointing results with cytokine-directed antibodies is the redundancy of the cytokine system. Neutralizing the activity of one cytokine probably makes another take over. The striking redundancy of the cytokine system was again demonstrated by the finding, that IL-2 and IL-4 knock-out mice were less affected in the development and function of their T cell system than expected.73. 4 Another approach to interfere in the cytokine network, by using mAb directed against the IL-2R (CD25), has been shown to be more successful. Not only the number of publications on the use of this mAb, but also the fact that this treatment is already used in clinical trials, are indicative for its success. Anti-IL-2R mAb therapy differs from anti-cytokine mAb therapy in that it acts on IL-2R bearing cells 
